PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
NASDAQ:PCRX • US6951271005
22.695 USD
+0.93 (+4.25%)
Last: Feb 17, 2026, 02:50 PM
We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 191 industry peers in the Pharmaceuticals industry. While PCRX has a great profitability rating, there are some minor concerns on its financial health. PCRX is valued quite cheap, but it does not seem to be growing. With these ratings, PCRX could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
- In the past year PCRX was profitable.
- PCRX had a positive operating cash flow in the past year.
- Of the past 5 years PCRX 4 years were profitable.
- PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- PCRX has a better Return On Assets (1.65%) than 81.15% of its industry peers.
- Looking at the Return On Equity, with a value of 2.95%, PCRX belongs to the top of the industry, outperforming 82.20% of the companies in the same industry.
- PCRX has a better Return On Invested Capital (3.63%) than 82.20% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 12.64%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- With an excellent Profit Margin value of 2.99%, PCRX belongs to the best of the industry, outperforming 80.10% of the companies in the same industry.
- PCRX has a better Operating Margin (8.88%) than 81.15% of its industry peers.
- PCRX's Operating Margin has improved in the last couple of years.
- PCRX's Gross Margin of 79.17% is amongst the best of the industry. PCRX outperforms 84.29% of its industry peers.
- In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, PCRX has less shares outstanding
- PCRX has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, PCRX has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 1.86 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of PCRX (1.86) is better than 61.78% of its industry peers.
- The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
- PCRX has a better Debt to FCF ratio (3.03) than 91.10% of its industry peers.
- A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.52, PCRX is not doing good in the industry: 62.83% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.86 |
ROIC/WACC0.47
WACC7.77%
2.3 Liquidity
- PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of PCRX (5.26) is better than 64.92% of its industry peers.
- A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
- PCRX has a Quick ratio (3.78) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
- The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
- The Revenue for PCRX has decreased by -16.85% in the past year. This is quite bad
- PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- The Earnings Per Share is expected to grow by 7.01% on average over the next years.
- PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.79% yearly.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.79%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 7.64, which indicates a rather cheap valuation of PCRX.
- Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 94.24% of the companies listed in the same industry.
- PCRX is valuated cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 6.53 indicates a rather cheap valuation of PCRX.
- Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 93.72% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.06. PCRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.64 | ||
| Fwd PE | 6.53 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 96.86% of the companies listed in the same industry.
- PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 95.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.51 | ||
| EV/EBITDA | 5.99 |
4.3 Compensation for Growth
- The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.55
EPS Next 2Y4.05%
EPS Next 3Y6.92%
5. Dividend
5.1 Amount
- PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:PCRX (2/17/2026, 2:50:13 PM)
22.695
+0.93 (+4.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners114.44%
Inst Owner Change-0.98%
Ins Owners0.79%
Ins Owner Change16.54%
Market Cap932.76M
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (33.55%)
Short Float %19.55%
Short Ratio8.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-20.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.78%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)2.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.64 | ||
| Fwd PE | 6.53 | ||
| P/S | 1.3 | ||
| P/FCF | 7.51 | ||
| P/OCF | 6.59 | ||
| P/B | 1.28 | ||
| P/tB | 2.87 | ||
| EV/EBITDA | 5.99 |
EPS(TTM)2.97
EY13.09%
EPS(NY)3.48
Fwd EY15.31%
FCF(TTM)3.02
FCFY13.32%
OCF(TTM)3.44
OCFY15.16%
SpS17.44
BVpS17.69
TBVpS7.9
PEG (NY)N/A
PEG (5Y)0.55
Graham Number34.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 1.86 |
F-Score7
WACC7.77%
ROIC/WACC0.47
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.79%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.3%
EBIT Next 3Y6.32%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.64 and the Price/Book (PB) ratio is 1.28.